Table 3. Association of microRNA-222 expression level with clinicopathologic characteristics of breast carcinomas in subgroups according to hormone receptor status.
| Characteristics | Hormone receptor-positive subgroup (n = 145) | Hormone receptor-negative subgroup (n=52) | ||||
|---|---|---|---|---|---|---|
| miR-222 low, No. (%) | miR-222 high, No. (%) | p-value* | miR-222 low, No. (%) | miR-222 high, No. (%) | p-value* | |
| Age (yr) | 0.300 | 0.013 | ||||
| < 50 | 33 (48.5) | 44 (57.1) | 20 (66.7) | 7 (31.8) | ||
| ≥ 50 | 35 (51.5) | 33 (42.9) | 10 (33.3) | 15 (68.2) | ||
| T stage | 0.001 | 0.190 | ||||
| T1 | 45 (66.2) | 30 (39.0) | 12 (40.0) | 5 (22.7) | ||
| T2–T3 | 23 (33.8) | 47 (61.0) | 18 (60.0) | 17 (77.3) | ||
| N stage | 0.368 | 0.093 | ||||
| N0 | 32 (47.1) | 42 (54.5) | 23 (76.7) | 12 (54.5) | ||
| N1–N3 | 36 (52.9) | 35 (45.5) | 7 (23.3) | 10 (45.5) | ||
| Histologic grade | < 0.001 | 1.000 | ||||
| I, II | 62 (91.2) | 43 (55.8) | 2 (6.7) | 1 (4.5) | ||
| III | 6 (8.8) | 34 (44.2) | 28 (93.3) | 21 (95.5) | ||
| Lymphovascular invasion | 0.543 | 0.189 | ||||
| Absent | 31 (45.6) | 39 (50.6) | 24 (80.0) | 14 (63.6) | ||
| Present | 37 (54.4) | 38 (49.4) | 6 (20.0) | 8 (36.4) | ||
| p53 overexpression | 0.040 | 0.099 | ||||
| Absent | 64 (94.1) | 64 (83.1) | 15 (50.0) | 6 (27.3) | ||
| Present | 4 (5.9) | 14 (16.9) | 15 (50.0) | 16 (72.7) | ||
| Ki-67 index (%) | < 0.001 | 1.000 | ||||
| < 20 | 65 (95.6) | 45 (58.4) | 2 (6.7) | 2 (9.1) | ||
| ≥ 20 | 3 (4.4) | 32 (41.6) | 28 (93.3) | 20 (90.9) | ||
| HER2 | < 0.001 | < 0.001 | ||||
| Negative | 67 (98.5) | 58 (75.3) | 30 (100) | 4 (18.2) | ||
| Positive | 1 (1.5) | 19 (24.7) | 0 | 18 (81.8) | ||
miR-222=microRNA-222; HER2=human epidermal growth factor receptor 2.
*p-values were calculated by the chi-square or Fisher exact test.